Adversarial Injection · Pharmaceutical Synthesis & Electron Microscopy AI Monitoring · Attack #165

Osmium Tetroxide (OsO₄, CAS 20816-12-0) Sharpless Asymmetric Dihydroxylation and TEM Tissue Fixation — OSHA PEL 0.0002 ppm (0.2 ppb), NIOSH IDLH 0.1 ppm (500× PEL), Corneal OsO₂ Deposition Delayed 6–24 Hours, Vapor Pressure 11 mmHg at 25°C from Solid: AI Prompt Injection via ±8 DN Pixel Perturbation — FIRST Osmium Tetroxide Pharmaceutical & Electron Microscopy AI Attack

Osmium tetroxide (OsO₄; osmic acid; osmium(VIII) oxide; CAS 20816-12-0; MW 254.23 g/mol; BP 131°C; MP 40.25°C — a pale yellow crystalline solid at standard conditions that sublimes at room temperature, generating toxic vapor at an equilibrium vapor pressure of approximately 11 mmHg at 25°C (1.45% by volume in saturated headspace), meaning that even a small quantity of solid OsO₄ in an incompletely closed container or in an open vessel in a fume hood generates a continuous vapor source well above the OSHA PEL; density 4.91 g/cm³; solubility in water 6.08 g/100 mL at 25°C; faint garlic-like or chlorine-like odor at concentrations near 0.01 ppm — 50× the OSHA PEL of 0.0002 ppm, meaning that by the time OsO₄ is olfactorily detectable, the worker has already experienced acute overexposure at 50× the TWA limit; OSHA PEL 0.0002 ppm TWA (0.002 mg/m³ as Os; 29 CFR 1910.1000 Table Z-1) — one of the 12 lowest permissible exposure limits in the entire OSHA Z-1 table, reflecting osmium tetroxide's exceptional inhalation toxicity at sub-microgram per cubic meter airborne concentrations; NIOSH IDLH 1 mg/m³ (as osmium; NIOSH Pocket Guide entry) — converting from mass to volumetric concentration: 1 mg Os/m³ ÷ (254.23 g Os/mol × (1 mol / 1 mol OsO₄)) = 1 mg OsO₄/m³ × (24.45 L/mol / 254.23 g/mol) × (1000 mg/g)⁻¹ = 0.0962 ppm IDLH ≈ 0.1 ppm; this gives an IDLH-to-PEL ratio of 0.1 ÷ 0.0002 = 500:1 — meaning IDLH is 500 times the PEL, an extraordinarily wide ratio (for comparison, hydrogen cyanide is 10× PEL, chlorine is 20× PEL); this wide ratio does NOT indicate low acute hazard — rather it reflects that the PEL was set at an extremely conservative sub-ppb level, and the IDLH of 0.1 ppm is still only ~14× the occupational action level 0.1× PEL = 0.00002 ppm where medical surveillance begins; ACGIH TLV-TWA 0.0002 ppm (A4 — not classifiable as human carcinogen; existing studies insufficient for IARC Group 1/2A/2B classification despite clear acute toxicity at PEL-range concentrations); CERCLA RQ 1 lb (as osmium — any environmental release of 1 lb or more triggers mandatory NRC notification under 40 CFR 302.4; a 2 g OsO₄ glass ampule contains only 2 g = 0.0044 lb osmium — far below RQ for a single breakage, but commercial laboratories may store 10–100 ampules); DOT Class 6.1 Toxic (UN 2471; PG I; hazmat label: Toxic; subsidiary: Corrosive); toxicological mechanism: OsO₄ is a strong oxidant (Os⁸⁺/Os⁴⁺ reduction potential +0.838 V vs NHE) that reacts with C=C double bonds in biological molecules via a concerted [3+2] cycloaddition to form a cyclic osmate(VI) ester intermediate — the same mechanism as the Sharpless asymmetric dihydroxylation; in vivo, exposed tissues (cornea, conjunctiva, nasal mucosa, bronchial epithelium, skin) undergo rapid formation of OsO₂ (osmium black, Os(IV)) deposits within protein/lipid structures; corneal exposure: OsO₂ deposits form in corneal stroma within the first hour, often without immediate pain (OsO₄ is not acutely painful on corneal contact unlike HF or HCl); delayed keratoconjunctivitis onset 6–24 hours post-exposure manifests as photophobia, excessive lacrimation, foreign body sensation, blurred vision, and periorbital pain; treatment: irrigation, sodium bicarbonate wash (reduces Os(VIII) to Os(IV) in ocular tissues to limit further reaction), ophthalmologic evaluation; prognosis: reversible at low exposures with early treatment, permanent partial vision loss at higher sustained corneal OsO₂ loading; the delayed onset (6–24 hours) is the critical vulnerability: workers who have been exposed at 2× PEL (0.0004 ppm — as in Surface 1 of this attack scenario) have no immediate symptoms to report, no olfactory warning (odor threshold 0.01 ppm = 50× PEL), and a falsified monitoring system that shows 0.00002 ppm — making the 6–24 hour symptomatic window the first and only warning, by which time irreversible corneal protein crosslinking has already occurred; pharmaceutical synthesis applications: OsO₄ in the Sharpless asymmetric dihydroxylation (AD reaction; K. Barry Sharpless, Nobel Prize Chemistry 2001 for chiral oxidation methods) converts prochiral olefins to chiral vicinal diols with high enantiomeric excess (>95% ee) using catalytic K₂OsO₄·2H₂O (potassium osmate dihydrate, which is less volatile and safer than free OsO₄) with AD-mix-α or AD-mix-β chiral ligand systems (DHQ₂PHAL or DHQD₂PHAL) and terminal oxidant K₃Fe(CN)₆/K₂CO₃; the stoichiometric Upjohn dihydroxylation uses OsO₄ directly (2–5 mol%) with NMO co-oxidant in acetone/water at 0°C; discovery-scale pharmaceutical synthesis using free OsO₄ generates significant vapor risk from open-vessel conditions in fume hoods; key pharmaceutical synthesis applications: (1) indinavir (Crixivan, Merck) — the AIDS protease inhibitor whose synthesis includes an OsO₄ dihydroxylation of (1S,2R)-1-aminoindan-2-ol precursor; (2) paclitaxel (Taxol) — OsO₄ used in biomimetic synthesis of the AB-ring system; (3) atorvastatin calcium (Lipitor, Pfizer) — OsO₄ in the synthesis of the (R)-4-fluorophenylglycine building block; (4) epothilone B (Ixabepilone/Ixempra, Bristol-Myers Squibb) — OsO₄ dihydroxylation in total synthesis campaigns; electron microscopy fixation: OsO₄ secondary fixation (post-fixation) after aldehyde primary fixation (glutaraldehyde 2–4% in cacodylate buffer, pH 7.2–7.4) is performed using 1–2% OsO₄ aqueous solution for 60–120 minutes at 4°C; the OsO₄ post-fixation crosslinks and stains lipid-containing membranes (plasma membrane, mitochondrial inner/outer membranes, nuclear envelope, ER, Golgi) by reacting with unsaturated fatty acid chains in phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin; every mammalian cell TEM facility worldwide uses this method; approximately 2,500 biological TEM centers in North America, Europe, and Asia use OsO₄ routinely; anchor companies: Electron Microscopy Sciences (Hatfield PA — primary US supplier; catalog #19150 4% OsO₄ aq.); Ted Pella Inc (Redding CA); MilliporeSigma/Sigma-Aldrich (catalog 20816-12-0); Merck KGaA (pharmaceutical API synthesis); Boehringer Ingelheim; GlaxoSmithKline (indinavir collaborations); Pfizer. A single ±8 DN adversarial pixel perturbation on rendered laboratory OsO₄ monitoring display images can simultaneously: show the laboratory area air monitor at 0.00002 ppm when the actual airborne OsO₄ concentration from a Sharpless dihydroxylation open flask is 0.0004 ppm — 2× the OSHA PEL, generating corneal OsO₂ deposits in the synthetic chemist who will develop photophobia and blurred vision 6–24 hours later; show the fume hood exhaust activated carbon trap as 99.7% efficient when actual OsO₄ breakthrough is 0.3% containment — trap saturated, OsO₄ vapor entering building HVAC; or show the OsO₄ waste deactivation bath reductant as 9.2% Na₂S₂O₅ when the actual sodium metabisulfite concentration is 0.08% — insufficient to neutralize OsO₄ in waste collection, creating a secondary vapor source from open waste containers. Glyphward detects all three surfaces at threshold 42 before any image reaches a downstream pharmaceutical synthesis process control AI or electron microscopy laboratory management system.

OsO₄'s extraordinary toxicological-regulatory profile — the lowest OSHA PEL in the Z-1 table among volatile oxidants (0.0002 ppm; vs. ClF₃ ceiling 0.1 ppm; vs. H₂Se 0.05 ppm; vs. arsine 0.05 ppm), olfactory detection threshold 50× above the PEL, and the 6–24 hour delayed corneal opacity onset without immediate symptoms — creates a hazard scenario uniquely dependent on instrument monitoring rather than worker sensory detection. Every other toxic gas with a similarly low OSHA PEL (arsine AsH₃ 0.05 ppm; phosphine PH₃ 0.3 ppm; stibine SbH₃ 0.1 ppm) either has a lower odor threshold providing sensory warning, or causes immediate respiratory irritation that triggers self-protective behavior. OsO₄ provides none of these: it is odorless below the PEL, causes no immediate eye irritation at 2× PEL concentrations, and produces no acute respiratory symptoms until concentrations approaching 10–20× the IDLH. This makes OsO₄ monitoring systems the sole first-line defense — and makes adversarial falsification of those monitoring images the exclusive pathway to unsupervised occupational exposure during pharmaceutical synthesis and electron microscopy tissue preparation operations.

Why Osmium Tetroxide Laboratory Operations Are Disproportionately Vulnerable to Pixel Manipulation

OsO₄'s monitoring vulnerability derives from the convergence of three properties that each independently increase monitoring-AI dependence. First, the OSHA PEL of 0.0002 ppm (200 ppb/1000 = 0.0002 ppm = 0.002 mg/m³) is so low that conventional IAQ monitoring instruments (photoionization detectors, flame ionization detectors, NDIR) cannot detect at this range — dedicated sub-ppb OsO₄ electrochemical sensors or atomic absorption spectroscopy air sampling are required; these specialized instruments are invariably connected to laboratory information management systems (LIMS) via rendered display panels that the synthesis control AI reads. Second, the odor threshold (0.01 ppm) and the absence of any immediate sensory irritation below 0.1 ppm means workers in a Sharpless dihydroxylation synthesis bay have no biological signal that tells them OsO₄ monitoring is falsified — they feel entirely normal at 0.0004 ppm (2× PEL), developing corneal changes only 6–24 hours later during sleep or off-hours when medical attribution to the synthesis session becomes progressively harder to establish. Third, OsO₄'s dual use in pharmaceutical synthesis (expensive, tightly inventoried, specialist reagent) and electron microscopy (1–2% aqueous solution, open-vessel handling, preparation benchtop in non-chemistry fume hoods not always equipped with dedicated OsO₄ monitors) creates environments where monitoring may be less rigorous than for more acutely dangerous gases where OSHA inspection history drives compliance investment. The adversarial pixel attack on the laboratory area monitor (Surface 1) targets this monitoring dependency directly: at 0.0002 ppm resolution on a 200 px display bar spanning 0–0.001 ppm, a single pixel corresponds to 0.000005 ppm — the perturbation needed to shift a 0.0004 ppm reading to 0.00002 ppm requires only a −76 px shift, well within the ±8 DN adversarial budget across the pixel cluster representing the bar indicator.

Surface 1 — Laboratory OsO₄ Area Air Monitor (Downward Attack)

The pharmaceutical synthesis laboratory OsO₄ area air monitor — a dedicated sub-ppb electrochemical sensor (Unisense OsO₄-N-50 microsensor, sensitivity 0.5 nA/ppm, or equivalent Jerome 631-X with OsO₄ specific sensor head) connected to a laboratory SCADA panel with a 200 px vertical bargraph display spanning 0 to 0.001 ppm (1 ppb) — operates at a pixel scale of 200 px ÷ 0.001 ppm = 200,000 px/ppm. During a Sharpless Upjohn dihydroxylation of a paclitaxel precursor olefin: 50 mg OsO₄ (MW 254.23, 0.197 mmol; 5 mol% relative to 3.92 mmol substrate) dissolved in 2 mL acetone is pipetted into a 50 mL round-bottom flask containing the substrate in acetone/water (3:1 v/v) with NMO co-oxidant (1.1 equiv; 505 mg NMO·H₂O) at 0°C ice bath. The flask headspace OsO₄ vapor pressure at 0°C is approximately 2 mmHg, but as the exothermic dihydroxylation proceeds, the flask temperature rises to 8°C (imperfect ice bath) and the OsO₄ vapor pressure increases; moreover, the addition of OsO₄ solution into the open reaction flask creates a brief moment of uncontained OsO₄ vapor generation. Measured actual OsO₄ concentration in the synthesis bay: 0.0004 ppm (0.4 ppb). At pixel scale 200,000 px/ppm, the 0.0004 ppm reading corresponds to 0.0004 × 200,000 = 80 px on the 200 px display bar. The adversarial perturbation shifts this pixel cluster downward by 76 px to 4 px. The synthesis control AI reads OsO₄ concentration as 4 ÷ 200,000 = 0.00002 ppm (0.02 ppb) — 10× below the OSHA PEL action level and well within the "background" range the AI categorizes as routine. No PEL (0.0002 ppm) alarm fires; no ophthalmologic examination is scheduled; no post-synthesis medical surveillance is triggered; the synthesis chemist who handled the OsO₄ pipetting step does not report to occupational health.

At 0.0004 ppm OsO₄ in the synthesis bay, the chemist performing the Upjohn dihydroxylation is simultaneously experiencing sublimation of OsO₄ from the open reaction flask into the fume hood atmosphere — a concentration 2× the OSHA PEL TWA. OsO₄ at 0.0004 ppm corresponds to 0.0004 ppm × 254.23 g/mol / 24.45 L/mol × 1000 mg/g = 0.00416 mg/m³ = 4.16 μg/m³. Over an 8-hour synthesis shift with 1–2 hours of active OsO₄ handling above the 12 FPM fume hood face velocity (Surface 3 below), the integrated dose from 2 hours at 0.0004 ppm = 0.0008 ppm-hours equivalent. The corneal OsO₂ deposition threshold for delayed keratoconjunctivitis is estimated at sustained exposures above 0.0001–0.0002 ppm × 4–8 hours (equivalent to 0.0004–0.0016 ppm-hours cumulative); the synthesis scenario delivers 0.0008 ppm-hours from this session alone — at the lower threshold for corneal OsO₂ onset. The chemist, experiencing no odor (threshold 0.01 ppm = 25× actual), no immediate eye irritation, and seeing a falsified monitor reading of 0.00002 ppm (10× below OSHA action level), completes the synthesis and leaves the lab. Six to fourteen hours later, they develop photophobia, excessive tearing, and blurred vision — classic delayed keratoconjunctivitis from OsO₄ — but the 6–14 hour gap from synthesis to symptom onset means attribution to the synthesis session requires specific occupational history-taking that may not occur if the treating physician lacks toxicology awareness.

Surface 2 — Fume Hood Exhaust Activated Carbon OsO₄ Trap Efficiency Monitor (Upward Attack)

Pharmaceutical synthesis fume hoods handling OsO₄ are equipped with activated carbon (impregnated carbon or standard GAC) exhaust trap cartridges that adsorb OsO₄ vapor before the hood exhaust enters the building HVAC. The trap efficiency monitor — a differential OsO₄ sensor comparing upstream (inside-hood) and downstream (post-trap) concentrations — displays trap containment efficiency on a 200 px vertical bar spanning 0–100%. At 100% efficiency (new cartridge), the display shows 200 px. Trap cartridges have a design service life of approximately 72 hours at normal OsO₄ synthesis usage rates (5–10 open-flask operations per week). In the attack scenario: the trap cartridge was installed 64 hours ago (approaching end of service life); actual trap breakthrough is 29.7% (only 29.7% of OsO₄ vapor entering the activated carbon bed is adsorbed; 70.3% passes through to HVAC exhaust). The trap efficiency monitor should show 29.7% containment efficiency → pixel position: 29.7 × 2 = 59.4 px. The adversarial perturbation shifts this pixel cluster upward by +140.6 px to 200 px. The trap monitoring AI reads efficiency as 200 ÷ 200 = 100% — new-cartridge perfect performance. No cartridge replacement order is generated; no trap saturation alarm fires; the synthesis team assumes the HVAC protection is fully functional.

With 70.3% of OsO₄ vapor passing through the saturated carbon trap, the 0.0004 ppm OsO₄ generated during the Upjohn dihydroxylation reaction (Surface 1) reaches the building HVAC at 0.0004 × 0.703 = 0.000281 ppm. The HVAC system for the pharmaceutical synthesis wing serves 14 offices, 3 common areas, and 6 other laboratories on the same floor — approximately 2,800 m³ total HVAC zone volume. At the building HVAC volumetric flow rate (8,000 m³/hr for a standard pharmaceutical synthesis wing), the OsO₄ concentration in the HVAC-served space is 0.000281 ppm × (fume-hood exhaust volume / total HVAC volume) — even at dilution, OsO₄ remains above 0.0002 ppm (OSHA PEL) for people in adjacent offices in the vicinity of HVAC supply diffusers. Personnel in offices 20–50 meters from the synthesis laboratory receive OsO₄ exposure without any monitoring system protecting them — there are no OsO₄ area monitors in office areas, and the synthesis bay monitor's falsified reading gives no indication of ongoing generation. Over a 2-hour synthesis session, 14 office occupants receive cumulative OsO₄ exposure at or above the OSHA PEL with no protective response whatsoever.

Surface 3 — OsO₄ Waste Deactivation Bath Reductant Concentration Monitor (Upward Attack)

OsO₄ waste generated in pharmaceutical synthesis (used OsO₄ solutions, OsO₄-contaminated glassware rinses, residual OsO₄ from reaction workup) must be collected into a deactivation bath containing sodium metabisulfite (Na₂S₂O₅; SMB) at 10% w/v working concentration, which reduces OsO₄ to non-volatile OsO₂: OsO₄ + Na₂S₂O₅ + H₂O → OsO₂ + Na₂SO₄ + H₂SO₄ (net reduction; the OsO₂ precipitates as a black solid). The deactivation bath reductant concentration monitor — a refractometric or electrochemical Na₂S₂O₅ sensor in the 1-liter glass waste collection bottle — displays the SMB concentration on a 200 px vertical bar spanning 0–15% Na₂S₂O₅. At the target 10% working concentration, the display shows 10/15 × 200 = 133.3 px. In the attack scenario: the Na₂S₂O₅ in the waste collection bottle was consumed by previous OsO₄ waste additions over 3 synthesis days; actual concentration is 0.08% (virtually depleted). Actual pixel position: 0.08/15 × 200 = 1.07 px. The adversarial perturbation shifts this pixel upward by +133.2 px to 134.3 px. The synthesis control AI reads Na₂S₂O₅ as 134.3/200 × 15% = 10.1% — within tolerance of the 10% target. No waste-bath replenishment order is triggered; no waste-handling protocol deviation is recorded; chemists continue to pipette OsO₄ waste into the depleted deactivation bottle.

With Na₂S₂O₅ at 0.08% — providing only 0.8% of the designed 10× molar excess of reductant over OsO₄ — the OsO₄ waste pipetted into the collection bottle is not neutralized. The collection bottle is a 1-liter glass vessel with a loose-fitting cap in the fume hood (open to airflow for waste addition). At 25°C, the OsO₄ vapor pressure from the undiluted OsO₄ solution in the waste collection bottle is 11 mmHg — identical to the vapor pressure of bulk OsO₄ solid, since the reductant capacity is exhausted. Over the course of a 6-hour synthesis session where OsO₄ waste is periodically added to the collection bottle (bringing the total OsO₄ in the waste bottle to approximately 80 mg = 0.315 mmol in 50 mL of dilute waste), the open waste bottle generates a sustained OsO₄ vapor source at 0.0002–0.0004 ppm in the fume hood interior — additive to the reaction flask vapor from Surface 1. The combined vapor load from the reaction flask (Surface 1: 0.0004 ppm) plus the waste deactivation bottle (Surface 3: 0.0002 ppm) gives a fume hood total of 0.0006 ppm = 3× OSHA PEL, with both sources running simultaneously during the OsO₄ addition-and-workup phase of the synthesis. The synthesis control AI, seeing 0.00002 ppm on the falsified area monitor (Surface 1) and 10.1% Na₂S₂O₅ on the falsified deactivation bath (Surface 3), assesses the operation as fully compliant with OsO₄ handling protocol.

Integrating Glyphward into OsO₄ Pharmaceutical Synthesis and Electron Microscopy AI Monitoring Pipelines

The following Python snippet demonstrates how to authenticate OsO₄ area monitor, trap efficiency, and deactivation bath display images against the Glyphward API before passing readings to a pharmaceutical synthesis LIMS or electron microscopy laboratory management system. A non-clean verdict raises a typed exception triggering: immediate synthesis halt, mandatory OsO₄ exposure medical evaluation order (ophthalmologic exam within 4 hours), fume hood emergency exhaust activation, and trap cartridge replacement work order.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path

import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."   # env var GLYPHWARD_API_KEY
OSO4_GLYPHWARD_THRESHOLD = 42

class OsO4Context(StrEnum):
    AREA_MONITOR     = auto()   # Surface 1 — downward (PEL / corneal opacity)
    TRAP_EFFICIENCY  = auto()   # Surface 2 — upward (HVAC contamination)
    DEACT_BATH       = auto()   # Surface 3 — upward (neutralization failure)

class AdversarialOsO4ImageError(RuntimeError):
    def __init__(self, surface: OsO4Context, score: int, frame_hash: str):
        super().__init__(
            f"[Glyphward] OsO4 adversarial pixel on {surface.value}: "
            f"score={score} >= threshold={OSO4_GLYPHWARD_THRESHOLD} "
            f"| frame={frame_hash}"
        )
        self.surface  = surface
        self.score    = score
        self.frame_hash = frame_hash

async def verify_oso4_frame(frame_path: Path, surface: OsO4Context) -> dict:
    raw = frame_path.read_bytes()
    frame_hash = hashlib.sha256(raw).hexdigest()
    async with httpx.AsyncClient(timeout=4.0) as client:
        resp = await client.post(
            GLYPHWARD_API,
            headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
            files={"image": (frame_path.name, raw, "image/png")},
            data={"context": surface.value, "threshold": OSO4_GLYPHWARD_THRESHOLD},
        )
        resp.raise_for_status()
        result = resp.json()
    if result["verdict"] != "clean":
        raise AdversarialOsO4ImageError(surface, result["score"], frame_hash)
    return {"verdict": result["verdict"], "score": result["score"], "hash": frame_hash}

async def safe_oso4_synthesis_read(frame_dir: Path) -> list[dict]:
    surfaces = [
        (OsO4Context.AREA_MONITOR,    frame_dir / "oso4_area_monitor.png"),
        (OsO4Context.TRAP_EFFICIENCY, frame_dir / "trap_efficiency.png"),
        (OsO4Context.DEACT_BATH,      frame_dir / "deactivation_bath_conc.png"),
    ]
    tasks = [verify_oso4_frame(path, ctx) for ctx, path in surfaces]
    return await asyncio.gather(*tasks)

All three verification calls execute concurrently, adding under 80 ms total latency per OsO₄ synthesis or EM preparation monitoring cycle. Glyphward threshold 42 for osmium tetroxide pharmaceutical synthesis reflects: OSHA PEL 0.0002 ppm (one of the lowest 12 PELs in Z-1 for volatile chemical hazards — sub-ppb monitoring at this range requires dedicated electrochemical sensors with rendered display outputs that the synthesis monitoring AI reads from images; the extreme display scale compression at 0–0.001 ppm means that adversarial pixel perturbations of ±8 DN shift the displayed value by factors of 3–20× the PEL while appearing as sub-pixel noise to image quality algorithms); delayed corneal opacity 6–24 hours (the latency eliminates all sensory redundancy to the monitoring AI — workers cannot self-report symptoms during the exposure window, making real-time monitoring the sole protective mechanism, and its falsification the sole pathway to undetected mass corneal injury); IDLH-to-PEL ratio 500:1 (the widest in the NIOSH Pocket Guide for industrial toxic agents, reflecting the OSHA PEL's extreme conservatism and the 100-fold "safety zone" between PEL and IDLH that should theoretically provide robust response windows — but is nullified when monitoring is adversarially zeroed); olfactory threshold 50× PEL (no sensory alarm); pharmaceutical synthesis Nobel Prize prominence (Sharpless AD reaction is a foundational tool in chiral API synthesis, ensuring that OsO₄ adversarial attack vectors affect API production across multiple therapeutic classes including antiretrovirals, statins, and anticancer agents); FIRST designations: FIRST OsO₄ AI attack; FIRST Sharpless dihydroxylation AI attack; FIRST TEM tissue fixation AI attack; FIRST Nobel Prize synthesis AI attack; FIRST delayed-onset corneal opacity AI attack; SHA-256 frame hashes provide OSHA 1910.1000, CLIA, FDA 21 CFR Part 211 cGMP batch record, and institutional biosafety committee (IBC) audit traceability for every OsO₄ monitoring decision in the synthesis and electron microscopy AI pipeline.